Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511614 · ClinicalTrials.gov registry record · NA
Nicotine Withdrawal Symptoms and Smoking Relapse
A NA study of Nicotine Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT01511614 is a NA study of Nicotine Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 112 participants, below the 185-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01511614, a NA study of Nicotine Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Smoking is thought to cause changes in the brain that lead to addiction and craving. Smokers who try to quit experience nicotine withdrawal symptoms that include irritability, anxiety, and difficulty concentrating. These symptoms make it difficult for people to stop smoking. Many people say that they continue smoking to help relieve these symptoms, often within the first week after trying to quit. Researchers want to study what is happening in the brain to cause these symptoms, which may help identify new ways to successfully quit smoking. Objectives: \- To study nicotine withdrawal symptoms and brain function in smokers who stop smoking for 36 hours. Eligibility: \- Individuals between 18 and 65 years of age who smoke at least 10 cigarettes per day. Participants must be able to stop smoking for 36 hours on two occasions. Design: Phase 1 * This study will involve three visits to the National Institute on Drug Abuse. * NOT be able to smoke for 36 hours before the two imaging visits. * Wear a nicotine skin patch or a placebo (fake) patch during your 36 hour smoking abstinence period and study visits. * Have your blood drawn to test for levels of stress-related hormones. * Complete multiple MRI scanning sessions that last about 1.5 to 2 hours each. * Undergo EEG (brain waves) recording. * Answer questionnaires about how you think and feel. * Complete various tasks and procedures inside and outside of the MRI scanner. Phase 2 * This study will involve thirteen visits to the National Institute on Drug Abuse. * Set a quit date and develop a treatment plan with a study therapist. * Take Chantix (varenicline) every day for a period of 12 weeks. * Meet for weekly and biweekly counseling sessions with a therapist. * Answer questionnaires about how you think and feel. Phase 3 * This study will involve three visits to the National Institute on Drug Abuse. * Complete an MRI scanning session that will last about 20min each visit * Meet with a study staf
Conditions Studied
Interventions
- DEVICE Transcranial Direct Current Stimulation
- DRUG Varenicline Pill
- DRUG Nicotine patch
- DEVICE sham
- DRUG Placebo patch
Study Locations (1)
Maryland
- National Institute on Drug Abuse - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2013-05-20 |
| Est. Completion | 2020-03-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511614
The ClinicalTrials.gov registry entry for NCT01511614 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (39% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 5 interventions - of which Transcranial Direct Current Stimulation is the first listed.
NCT01511614 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01511614 about?
NCT01511614 is a clinical study titled "Nicotine Withdrawal Symptoms and Smoking Relapse". Background: \- Smoking is thought to cause changes in the brain that lead to addiction and craving. Smokers who try to quit experience nicotine withdrawal symptoms that include irritability, anxiety, and difficulty concentrating. These symptoms make it difficult for people to stop smoking. Many peo...
What is the current status of trial NCT01511614?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2013-05-20. Estimated completion is 2020-03-30.
What conditions does trial NCT01511614 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT01511614?
The interventions under investigation include: Transcranial Direct Current Stimulation (DEVICE), Varenicline Pill (DRUG), Nicotine patch (DRUG), sham (DEVICE), Placebo patch (DRUG).
Who is sponsoring clinical trial NCT01511614?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01511614 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
NeuroControl of Nicotine Dependence
RECRUITING · NA
-
Abuse Liability and Appeal of Oral Nicotine Products
RECRUITING · NA
-
Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.